

17	7-METHOXYCOUMARIN	MTW/UM/2.1/5554/10	176.17
18	METHYL LINOLEATE	MTW/UM/2.1/3545/10	294.48
19	GERMACRENE	MTW/UM/2.1/8988/10	204.35
20	METHYL STEARATE	MTW/UM/2.1/3990/10	298.51
21	ALLICIN	MTW/UM/2.1/6621/10	162.27

UNKNOWN MASSES	
187	875
345	900
675	555
890	777
678	240
987	872
1098	982
456	567
789	355
987	092
345	
567	
164	
198	
902	
576	

PASS ANALYSIS

ALLICIN

0,998	0,000	Inflammatory Bowel disease treatment
0,998	0,001	Platelet antagonist
0,997	0,001	Atherosclerosis treatment
0,996	0,000	Antioxidant
0,997	0,001	Lipoprotein disorders treatment
0,996	0,001	Platelet aggregation inhibitor
0,995	0,001	Antileukemic
0,996	0,002	Antidiabetic
0,986	0,004	Antineoplastic
0,984	0,001	CYP2E1 inhibitor
0,980	0,001	Antiprotozoal
0,942	0,004	Apoptosis agonist
0,942	0,003	Lipid metabolism regulator
0,935	0,002	Antiprotozoal (Amoeba)
0,913	0,001	TRPA1 agonist
0,854	0,001	Chemoprotective
0,838	0,004	Antihypercholesterolemic
0,832	0,025	Aspulvinone dimethylallyltransferase inhibitor
0,751	0,019	NADPH peroxidase inhibitor
0,741	0,011	Hypolipemic
0,730	0,007	Chloride peroxidase inhibitor
0,722	0,010	Fatty-acyl-CoA synthase inhibitor
0,733	0,042	Mucomembranous protector

GERMACRENE

0,897	0,005	Ubiquinol-cytochrome-c reductase inhibitor
0,877	0,002	Carminative
0,880	0,006	Antieczematic
0,879	0,017	CYP2C12 substrate
0,846	0,015	Testosterone 17beta-dehydrogenase (NADP+) inhibitor
0,834	0,013	CYP2J substrate
0,830	0,014	Alkenylglycerophosphocholine hydrolase inhibitor
0,808	0,005	Phosphatidylcholine-retinol O-acyltransferase inhibitor
0,799	0,005	Fibrinolytic
0,799	0,010	Glutamyl endopeptidase II inhibitor
0,782	0,005	All-trans-retinyl-palmitate hydrolase inhibitor
0,776	0,012	Alkylacetyl glycerophosphatase inhibitor
0,770	0,011	5-O-(4-coumaroyl)-D-quininate 3'-monooxygenase inhibitor

0,784	0,038	Aspulvinone dimethylallyltransferase inhibitor
0,759	0,018	Acylcarnitine hydrolase inhibitor
0,780	0,041	Phobic disorders treatment
0,732	0,002	NF-E2-related factor 2 stimulant
0,760	0,031	Mucomembranous protector
0,728	0,005	Adenomatous polyposis treatment
0,726	0,016	Ribulose-phosphate 3-epimerase inhibitor
0,735	0,027	Sugar-phosphatase inhibitor
0,707	0,004	H+-exporting ATPase inhibitor
0,721	0,030	Membrane permeability inhibitor
0,709	0,031	CYP2J2 substrate
0,701	0,034	Nicotinic alpha6beta3beta4alpha5 receptor antagonist

CONCLUSION

From the present study we conclude that the garlic extract contains a variety of promising compounds which is highly potential in terms of biological activity. The activity spectrum which we sketched showed that the identified compounds are very significant. The PASS analysis which we carried out in the promising compounds needs further studies like molecular docking and in-vivo works which will be a boon for the entire drug industry as the source for the compounds are cheap and easily available in whole over the world. More than twenty unknown compounds are found in the LCMS analysis of Allium sativum so we recommend and more than we are proceeding for the identification of the unknown compounds.

REFERENCES

1. Shafeeque .K, Hashim K.M; Comparative anti –angiogenesis study between Allicin Nanoparticle and normal allicin from Garlic (Allium sativum Linn) .European journal of experimental biology DOI: 10.21767/2248-9215.100068
2. Shafeeque .K; Nanotechnology in Allium sativum Linn with special emphasis to anti- Angiogenesis. Global Journal Research Analysis, DOI:10.15373/22778160
3. Prasan R. Bhandari. Garlic (Allium sativum L.): A review of potential therapeutic applications, International Journal of Green Pharmacy10.4103/0973- 8258. 102826
4. UP Singh, B Prithviraj, B.K Sarma, Mandavi Singh & AB Ray;Role of garlic(Allium sativum Linn) in human and plant disease .Indian journal of experimental biology Vol.39 PP 310-322
5. Natália Martins2, Spyridon Petropoulos1*, Isabel C.F.R. Ferreira2* ; Chemical composition and bioactive compounds of garlic (Allium sativum L.) as affected by pre- and post harvest